Literature DB >> 27277045

A Monte Carlo study on (223)Ra imaging for unsealed radionuclide therapy.

Akihiko Takahashi1, Kenta Miwa1, Masayuki Sasaki1, Shingo Baba2.   

Abstract

PURPOSE: Radium-223 ((223)Ra), an α-emitting radionuclide, is used in unsealed radionuclide therapy for metastatic bone tumors. The demand for qualitative (223)Ra imaging is growing to optimize dosimetry. The authors simulated (223)Ra imaging using an in-house Monte Carlo simulation code and investigated the feasibility and utility of (223)Ra imaging.
METHODS: The Monte Carlo code comprises two modules, hexagon and nai. The hexagon code simulates the photon and electron interactions in the tissues and collimator, and the nai code simulates the response of the NaI detector system. A 3D numeric phantom created using computed tomography images of a chest phantom was installed in the hexagon code. (223)Ra accumulated in a part of the spine, and three x-rays and 19 γ rays between 80 and 450 keV were selected as the emitted photons. To evaluate the quality of the (223)Ra imaging, the authors also simulated technetium-99m ((99m)Tc) imaging under the same conditions and compared the results.
RESULTS: The sensitivities of the three photopeaks were 147 counts per unit of source activity (cps MBq(-1); photopeak: 84 keV, full width of energy window: 20%), 166 cps MBq(-1) (154 keV, 15%), and 158 cps MBq(-1) (270 keV, 10%) for a low-energy general-purpose (LEGP) collimator, and those for the medium-energy general-purpose (MEGP) collimator were 33, 13, and 8.0 cps MBq(-1), respectively. In the case of (99m)Tc, the sensitivity was 55 cps MBq(-1) (141 keV, 20%) for LEGP and 52 cps MBq(-1) for MEGP. The fractions of unscattered photons of the total photons reflecting the image quality were 0.09 (84 keV), 0.03 (154 keV), and 0.02 (270 keV) for the LEGP collimator and 0.41, 0.25, and 0.50 for the MEGP collimator, respectively. Conversely, this fraction was approximately 0.65 for the simulated (99m)Tc imaging. The sensitivity with the LEGP collimator appeared very high. However, almost all of the counts were because of photons that penetrated or were scattered in the collimator; therefore, the proportions of unscattered photons were small.
CONCLUSIONS: Their simulation study revealed that the most promising scheme for (223)Ra imaging is an 84-keV window using an MEGP collimator. The sensitivity of the photopeaks above 100 keV is too low for (223)Ra imaging. A comparison of the fractions of unscattered photons reveals that the sensitivity and image quality are approximately two-thirds of those for (99m)Tc imaging.

Entities:  

Year:  2016        PMID: 27277045     DOI: 10.1118/1.4948682

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  4 in total

1.  The potential of 223Ra and 18F-fluoride imaging to predict bone lesion response to treatment with 223Ra-dichloride in castration-resistant prostate cancer.

Authors:  Iain Murray; Sarah J Chittenden; Ana M Denis-Bacelar; Cecilia Hindorf; Christopher C Parker; Sue Chua; Glenn D Flux
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-06-13       Impact factor: 9.236

2.  Automated cassette-based production of high specific activity [203/212Pb]peptide-based theranostic radiopharmaceuticals for image-guided radionuclide therapy for cancer.

Authors:  Mengshi Li; Xiuli Zhang; Thomas P Quinn; Dongyoul Lee; Dijie Liu; Falk Kunkel; Brian E Zimmerman; Daniel McAlister; Keith Olewein; Yusuf Menda; Saed Mirzadeh; Roy Copping; Frances L Johnson; Michael K Schultz
Journal:  Appl Radiat Isot       Date:  2017-05-10       Impact factor: 1.513

3.  Estimation of the lower limits for feasible Ra-223 SPECT imaging: a Monte Carlo simulation study.

Authors:  Akihiko Takahashi; Hibiki Ueno; Shingo Baba; Masayuki Sasaki
Journal:  Asia Ocean J Nucl Med Biol       Date:  2021

4.  Ra-223 SPECT for semi-quantitative analysis in comparison with Tc-99m HMDP SPECT: phantom study and initial clinical experience.

Authors:  Yoshiki Owaki; Tadaki Nakahara; Takeo Kosaka; Junichi Fukada; Atsuhiro Kumabe; Akira Ichimura; Mikoto Murakami; Kiyotaka Nakajima; Masahiro Fukushi; Kazumasa Inoue; Mototsugu Oya; Masahiro Jinzaki
Journal:  EJNMMI Res       Date:  2017-10-03       Impact factor: 3.138

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.